214150 - Classys, Inc.

214150 Summary

Medical Devices

Stock Price & Overview

₩31,800 +100 (+0.32%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩31,800 ≈ US$23 · Market cap ₩2.1tn (≈ $1.5bn)

214150 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	336.8	242.9	180.1	141.8	100.6	76.5	81.1	47.5	34.9	27.2	15.0
Cost of Revenue	75.7	51.8	39.7	33.6	22.7	15.5	17.2	12.7	10.7	8.6	3.7
Gross Profit	261.1	191.1	140.4	108.2	77.9	61.0	63.9	34.7	24.2	18.6	11.3
Selling, General & Administrative	90.5	68.7	50.8	39.3	26.1	20.4	22.2	17.3	13.4	10.3	7.3
Operating Income	170.6	122.4	89.6	68.9	51.7	40.6	41.7	17.5	10.8	8.3	4.0
Finance Income	10.1	24.2	8.7	2.6	4.2	1.2	0.5	0.4	0.2	0.6	1.0
Finance Costs	10.9	5.7	4.3	4.7	0.4	2.6	0.7	0.6	0.7	0.5	0.1
Pretax Income	168.6	127.9	93.8	96.8	55.6	39.3	41.7	17.8	-3.1	8.8	5.4
Income Tax Expense	36.7	30.4	19.6	21.4	11.8	1.1	8.3	2.9	2.0	1.7	0.8
Net Income	132.0	97.5	74.2	75.4	43.8	38.2	33.4	14.9	-5.1	7.1	4.7
Total Comprehensive Income	132.0	97.6	74.3	75.4	43.9	38.2	33.4	14.9	-5.1	7.1	4.7

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	704.6	608.4	375.4	331.4	216.4	137.5	113.7	75.7	63.2	22.0	12.5
Current Assets	295.8	234.2	185.7	147.8	73.1	83.0	57.6	26.6	27.7	18.4	10.0
Cash & Cash Equivalents	37.5	22.7	18.3	26.0	42.8	64.4	34.0	10.5	19.2	12.0	6.7
Inventories	30.1	30.0	19.4	23.4	16.5	9.9	8.7	5.9	5.1	4.0	1.7
Trade Receivables	48.4	36.9	17.3	8.0	2.1	3.5	3.1	2.5	2.3	1.7	0.8
Non-current Assets	408.9	374.2	189.7	183.6	143.2	54.5	56.0	49.1	35.5	3.6	2.5
Property, Plant & Equipment	199.7	193.2	139.0	104.2	80.7	50.1	51.1	46.1	32.0	0.5	0.5
Intangible Assets	139.6	140.9	2.8	1.5	1.1	0.8	0.7	0.2	0.1	0.0	0.0
Total Liabilities	153.0	155.7	91.9	101.9	52.6	13.8	25.7	24.6	28.1	5.7	3.2
Current Liabilities	80.2	128.9	29.2	36.2	16.8	13.4	25.5	14.8	14.4	5.5	3.1
Non-current Liabilities	72.8	26.8	62.7	65.6	35.8	0.3	0.3	9.8	13.7	0.2	0.1
Total Equity	551.7	452.6	283.5	229.6	163.7	123.8	87.9	51.0	35.1	16.3	9.2
Share Capital	6.6	6.6	6.5	6.5	6.5	6.5	6.4	6.2	6.0	5.5	5.5
Retained Earnings	547.5	336.1	271.0	204.2	133.1	93.2	58.0	25.5	11.1	16.2	9.1

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	163.9	102.8	64.6	54.8	36.4	38.1	39.0	16.0	8.6	5.8	2.9
Cash from Investing Activities	-109.0	-82.2	-48.2	-92.0	-92.5	6.7	-12.7	-20.3	-20.6	-0.5	-0.1
Purchase of Property, Plant & Equipment	12.9	4.1	4.5	27.5	32.6	0.8	6.2	14.8	31.7	0.2	0.1
Cash from Financing Activities	-39.5	-16.7	-25.6	21.1	30.7	-12.2	-2.5	-4.4	19.4	-0.0	-0.9
Dividends Paid	16.8	12.8	7.5	4.3	3.9	3.0	0.9	0.5	—	0.0	0.9
Net Change in Cash	15.4	3.8	-9.2	-16.2	-25.4	32.6	23.9	-8.7	7.4	5.3	1.8

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	105.5	87.2	93.4	83.0	83.3	77.1	74.4	59.4	58.7	50.4
Cost of Revenue	29.0	22.1	21.4	19.3	19.3	15.8	17.6	12.8	11.2	10.2
Gross Profit	76.5	65.0	72.0	63.7	64.0	61.3	56.8	46.6	47.5	40.2
Selling, General & Administrative	32.6	27.8	20.8	26.1	21.0	22.5	21.0	17.6	16.3	13.7
Operating Income	43.9	37.2	51.2	37.6	43.0	38.8	35.8	29.0	31.2	26.5
Finance Income	5.4	10.2	4.7	2.2	1.0	2.1	15.9	-3.1	4.9	6.5
Finance Costs	12.0	2.4	0.9	-3.0	11.5	1.3	-0.6	2.7	0.5	0.6
Pretax Income	36.6	44.8	54.3	42.8	31.9	39.6	38.9	22.4	34.5	32.1
Income Tax Expense	11.1	11.7	11.7	9.7	5.4	9.8	10.5	5.9	8.0	6.0
Net Income	25.5	33.2	42.7	33.1	26.5	29.7	28.4	16.5	26.6	26.1
Total Comprehensive Income	26.1	33.5	42.7	33.1	26.4	29.7	28.4	16.5	26.6	26.1

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	774.7	799.8	704.6	654.4	626.6	631.9	608.4	433.7	418.5	402.9
Current Assets	317.7	362.7	295.8	272.4	248.4	254.2	234.2	202.2	187.1	212.6
Cash & Cash Equivalents	78.7	102.1	37.5	35.1	55.4	39.2	22.7	3.2	24.3	50.6
Inventories	64.9	59.1	30.1	31.3	30.1	30.4	30.0	16.7	17.9	19.4
Trade Receivables	98.4	108.6	48.4	57.7	49.0	40.2	38.7	32.8	31.8	24.0
Non-current Assets	457.0	437.2	408.9	382.0	378.1	377.7	374.2	231.5	231.4	190.3
Property, Plant & Equipment	206.0	207.8	199.7	202.9	198.4	198.2	193.2	150.2	143.4	143.5
Intangible Assets	162.6	146.3	139.6	140.1	140.6	140.2	140.9	7.6	6.5	4.6
Total Liabilities	219.6	270.5	153.0	136.0	131.8	165.2	155.7	91.7	93.6	105.6
Current Liabilities	198.9	252.3	80.2	44.9	47.1	71.4	128.9	91.2	93.1	105.0
Non-current Liabilities	20.7	18.2	72.8	91.2	84.7	93.8	26.8	0.5	0.5	0.6
Total Equity	555.1	529.3	551.7	518.4	494.7	466.8	452.6	342.0	324.9	297.2
Share Capital	6.6	6.6	6.6	6.6	6.6	6.6	6.6	6.5	6.5	6.5
Retained Earnings	530.2	501.9	547.5	408.5	375.5	349.0	336.1	307.3	290.9	264.3

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	6.0	9.5	91.5	19.2	23.1	30.1	39.6	13.1	30.6	19.4
Cash from Investing Activities	26.8	66.4	-79.5	-36.1	21.4	-14.8	-19.5	-32.6	-43.2	13.0
Purchase of Property, Plant & Equipment	1.8	1.5	0.8	4.2	1.6	6.3	1.7	1.0	0.8	0.6
Cash from Financing Activities	-57.0	-11.2	-8.9	-3.7	-27.9	1.0	-1.3	-0.9	-13.6	-1.0
Dividends Paid	—	—	0.0	0.0	—	—	0.0	0.0	—	—
Net Change in Cash	-24.2	64.6	3.0	-20.5	16.6	16.3	18.9	-20.4	-26.1	31.4

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

214150 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	336.8	+38.6%	+33.4%	+34.5%	+36.5%
Operating income	170.6	+39.3%	+35.3%	+33.3%	+45.6%
Net income	132.0	+35.3%	+20.5%	+28.2%	+39.6%
EPS	₩2,023	+35.3%	+20.5%	+28.2%	+39.6%
Operating cash flow	163.9	+59.5%	+44.1%	+33.9%	+49.9%
Shareholders' equity	551.7	+21.9%	+33.9%	+34.8%	+50.5%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

214150 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	77.5%	78.7%	78.0%	76.3%	77.4%	79.7%
Operating margin	50.7%	50.4%	49.8%	48.6%	51.4%	53.1%
Net margin	39.2%	40.2%	41.2%	53.2%	43.5%	49.9%
Return on equity	26.3%	26.5%	28.9%	38.3%	30.5%	36.1%
Return on assets	20.1%	19.8%	21.0%	27.5%	24.8%	30.4%
Operating cash flow / revenue	48.7%	42.3%	35.9%	38.6%	36.2%	49.9%
Capex / revenue	3.8%	1.7%	2.5%	19.4%	32.4%	1.0%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 214150

Symbol	Last Price
214450Pharma Research Co., Ltd.	₩386,500 +1.4%
096530Seegene, Inc.	₩31,900 +1.1%
491000Livs Med, Inc.	₩34,500 +3.6%
041830In Body Co., Ltd.	₩61,100 +2.5%
445680Curiox Biosystems Co., Ltd.	₩47,650 -1.5%
458870Seers Co., Ltd.	₩21,350 +3.1%
137310SD Biosensor	₩6,160 -0.3%
377740Bio Note, Inc.	₩4,790 -0.2%
340570T & L Co., Ltd.	₩29,650 +1.2%
099190i-SENS, Inc.	₩16,470 +0.0%

Compare all 13 in Medical Devices

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.